147687-17-0

Basic information

• Product Name: 9-Benxyloxy-3-(2-Chloro ethyl)-2-methyl pyrido[1,2-a]pyrimidine-4-one
• Synonyms: 9-Benxyloxy-3-(2-Chloro ethyl)-2-methyl pyrido[1,2-a]pyrimidine-4-one;3-(2-Chloroethyl)-2-methyl-9-benzyloxy-4H-pyrido[1,2-a]pyrimidin-4-one (Paliperidone);3-(2-Chloroethyl)-2-methyl-9-benzyloxy-4H-pyrido[1,2-a]pyrimidin-4-one;2-a]pyriMidin-4-one;3-(2-chloroethyl)-2-Methyl-9-(phenylMethoxy)-;4H-Pyrido[1;4H-Pyrido[1,2-a]pyriMidin-4-one, 3-(2-chloroethyl)-2-Methyl-9-(phenylMethoxy)-;3-(2-Chloroethyl)-2-Methyl-9-(phenylMethoxy)-4H-pyrido[1,2-a]pyriMidin-4-one
• CAS NO: 147687-17-0
• Molecular Formula: C₁₈H₁₇ClN₂O₂
• Molecular Weight: 328.79
• EINECS: 1312995-182-4
• Product Categories: APIs Intermediate;Bases & Related Reagents;Heterocycles;Nucleotides
• Mol File: 147687-17-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 140-142°C
• Boiling Point: 504.979 °C at 760 mmHg
• Flash Point: 259.202 °C
• Appearance: Off-white solid
• Density: 1.243 g/cm³
• Vapor Pressure: 2.53E-10mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 2.72±0.70(Predicted)
• CAS DataBase Reference: 9-Benxyloxy-3-(2-Chloro ethyl)-2-methyl pyrido[1,2-a]pyrimidine-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 9-Benxyloxy-3-(2-Chloro ethyl)-2-methyl pyrido[1,2-a]pyrimidine-4-one(147687-17-0)
• EPA Substance Registry System: 9-Benxyloxy-3-(2-Chloro ethyl)-2-methyl pyrido[1,2-a]pyrimidine-4-one(147687-17-0)

Safety Data

• Hazardous Substances Data: 147687-17-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 147687-17-0 differently. You can refer to the following data:
1. 3-(2-Chloroethyl)-2-methyl-9-(benzyloxy)-4H-pyrido[1,2a]pyrimidin-4-one is a compound useful in organic synthesis.
2. 3-(2-Chloroethyl)-2-methyl-9-(benzyloxy)-4H-pyrido[1,2a]pyrimidin-4-one (cas# 147687-17-0) is a compound useful in organic synthesis.

Chemical Properties

Off-White Solid

InChI:InChI=1/C18H17ClN2O2/c1-13-15(9-10-19)18(22)21-11-5-8-16(17(21)20-13)23-12-14-6-3-2-4-7-14/h2-8,11H,9-10,12H2,1H3

Upstream product

• 16867-03-1 2-amino-3-hydroxypyridine 
• 100-44-7 benzyl chloride 
• 24016-03-3 2-amino-3-benzyloxypyridine 
• 517-23-7 3-acetyl-2-oxo-4,5-dihydrofuran 
• 1008796-22-2 9-(benzyloxy)-3-(2-hydroxyethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one 

Downstream Products

• 849727-62-4 3-(2-chloroethyl)-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride 
• 1056034-13-9 C₃₀H₂₉FN₄O₃ 
• 1141761-79-6 C₃₀H₃₀F₂N₄O₃ 
• 260273-82-3 3-(2-chloroethyl)-2-methyl-9-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one 
• 849727-63-5 (±)-3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride 
• 130049-85-3 (+)-Paliperidone 
• 147663-01-2 (+)-9-hydroxyrisperidone 
• 1138463-56-5 3-(2-chloroethyl)-9-oxo-2-methyl-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]pyrimidin-4-one 
• 144598-75-4 paliperidone 
• 130049-82-0 3-(2-chloroethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 
• 849903-79-3 3-ethyl-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER

In an aspect, the disclosure pertains to inhibitors of ANGPTL4; synthesis methods for making disclosed compounds; pharmaceutical compositions comprising disclosed compounds; methods of treating disorders of uncontrolled cellular proliferation, e.g., a cancer; and methods of treating a disease associated with an ANGPTL4 dysfunction using disclosed compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Synthesis and absolute configuration assignment of 9-hydroxyrisperidone enantiomers

The enantiomers of 9-hydroxyrisperidone, the major metabolite of risperidone and the active component of the antipsychotic drug Invega , were synthesized by efficient methods. Their optical rotation and enantiomeric purity were characterized for the first time. The absolute configurations were assigned by comparing 1H NMR chemical shifts of Mosher esters of a key stereoisomeric intermediate. Thus, the stereoisomeric center of (+)-9-hydroxyrisperidone has been assigned as the S configuration, and its enantiomer has the configuration R.

PROCESS FOR THE PREPARATION OF PALIPERIDONE AND ITS INTERMEDIATES

A process for the preparation of a psychotropic agent Paliperidone. Preferably, this invention relates to a method for the purification of Paliperidone by making its acid addition salts.